Life Sciences: Greater competition, the cluster expansion, and the rise of bio-medical manufacturing
2021 was a record year for investment in life sciences companies but also in life sciences real estate. This interest was exemplified by the launch of the Life Science REIT in November, which raised £350m in an IPO, exceeding its target by £50m as well as BioMed Realty’s plans to double the size of its UK life sciences portfolio by delivering 800,000 sq ft of new stock.